Imukin

Recombinant human interferon gamma-1b, the active ingredient in Imukin, is an immunomodulator presented as a subcutaneous injectable for subcutaneous use. It is used to treat chronic granulomatous disease and severe malignant osteopetrosis in patients with these rare immune and bone disorders, by enhancing macrophage microbicidal activity, reducing infection-related morbidity, and supporting overall immune competence in affected patients.

GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imukin (recombinant human interferon gamma‑1b) is employed in rare disorders where enhancement of cellular immunity and bone remodeling is required, acting through the interferon‑gamma signaling pathway to boost host defenses.

- Chronic granulomatous disease: improves macrophage microbicidal activity, reduces severe bacterial and fungal infections, decreases infection‑related morbidity, and supports overall immune competence in affected patients. - Severe malignant osteopetrosis: stimulates osteoclast differentiation and function, facilitating bone resorption, improving skeletal remodeling, and helping to manage the excessive bone density characteristic of this disorder.

Imukin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Flu‑like symptoms: fever, chills, myalgia, and fatigue. - Injection site reactions: redness, swelling, or pain at the injection site. - Gastrointestinal upset: nausea, abdominal pain, or diarrhea. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hematologic abnormalities: anemia, leukopenia, or thrombocytopenia. - Hepatic dysfunction: elevated transaminases or hepatitis. - Autoimmune phenomena: development of lupus‑like syndrome or vasculitis. - Severe allergic reactions: anaphylaxis or serum sickness.

Prior to initiating Imukin, clinicians should consider several safety and handling precautions. - Pregnancy: potential risk to the fetus; use only if benefits outweigh risks. - Breastfeeding: unknown excretion in milk; caution advised. - Pre‑existing autoimmune disease: may exacerbate underlying condition. - Hepatic impairment: monitor liver function tests regularly. - Hematologic monitoring: periodic blood counts are recommended. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imukin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may increase risk of severe infection. - Immunosuppressants (e.g., high‑dose corticosteroids): may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., ribavirin): potential additive hematologic toxicity. - Anticoagulants (e.g., warfarin): possible alteration of coagulation parameters. - Cytotoxic chemotherapy: may enhance myelosuppression.